Skip to main content
FERMENTA BIOTECH LIMITED logo

FERMENTA BIOTECH LIMITED — Investor Relations & Filings

Ticker · FERMENTA ISIN · INE225B01021 LEI · 335800VNTNWW8G1U9314 BSE.NS Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2025-09-27 Board/Management Inform…
Country IN India
Listing BSE.NS FERMENTA

About FERMENTA BIOTECH LIMITED

https://fermentabiotech.com

Fermenta Biotech Limited is a specialized biotechnology company primarily focused on the development and manufacture of Vitamin D3 (Cholecalciferol). As one of the few vertically integrated manufacturers globally, the company produces Vitamin D3 for diverse applications, including pharmaceuticals, dietary supplements, human nutrition, and animal feed. Beyond its core Vitamin D3 portfolio, the company offers a range of specialty enzymes, particularly for the synthesis of beta-lactam antibiotics, and provides environmental solutions through its biotechnology expertise. Fermenta Biotech emphasizes high-quality standards, maintaining various international certifications for its manufacturing facilities. Its product offerings extend to premixes and value-added formats designed to meet specific formulation requirements. The company serves a global clientele, leveraging its research and development capabilities to innovate in the fields of nutrition and biotechnology.

Recent filings

Filing Released Lang Actions
Continual disclosure regarding re-appointment of Executive Directors.
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to the stock exchange (BSE Limited) regarding the re-appointment of two Executive Directors of the company. It references prior intimations and provides details about the re-appointments, including terms and brief profiles of the directors. The document cites compliance with SEBI Listing Regulations and includes an annexure with detailed director information. There are no financial statements, earnings data, or comprehensive management discussion. The content focuses solely on changes in the company's board of directors (executive management). The document length is 4261 characters, which is relatively short but contains substantive information about management appointments rather than just an announcement or a certification. Therefore, it fits best under the category of Board/Management Information (MANG).
2025-09-27 English
Press release regarding receipt of Great Place to work certification.
Regulatory Filings Classification · 95% confidence The document is a press release issued by Fermenta Biotech Limited announcing that the company has been certified as a Great Place to Work® for the year 2025-2026. It contains no financial data, no regulatory filings, no voting results, no management changes, no earnings or annual report content. The document is a public relations announcement about an employee culture certification, not a financial or regulatory report. It is also relatively short (9052 characters) and serves as a formal announcement to the stock exchange. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-09-23 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the Board of Directors' approval for the sale of the Environmental Solutions Business to a wholly owned subsidiary. It contains no financial statements, detailed financial analysis, or regulatory form references. The content focuses on a strategic business decision and operational restructuring rather than financial results or regulatory compliance filings. The document is about a corporate action announcement rather than a full report or detailed financial disclosure. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including business restructuring and asset sales.
2025-09-19 English
Sale of Company''s environment business to its wholly-owned subsidiary
Capital/Financing Update Classification · 95% confidence The document is a formal letter addressed to the stock exchange (BSE Limited) reporting the outcome of a Board of Directors meeting held on September 19, 2025. The key content is the approval of a Business Transfer Agreement (BTA) for the transfer of the environment business through a slump sale to a wholly owned subsidiary. The document includes detailed disclosures as required under SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, including financial figures, transaction details, related party transaction confirmation, and rationale for the transaction. The document is not a full financial report but an announcement of a significant corporate transaction approved by the Board. It is not a merger or acquisition filing per se, but a capital/financing update related to business restructuring. The length (9951 characters) and detailed disclosures indicate it is more than a brief announcement but does not contain financial statements or management discussion typical of annual or interim reports. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-09-19 English
Press release
Regulatory Filings Classification · 95% confidence The document is a press release issued by Fermenta Biotech Limited announcing the grant of a patent for a proprietary plant-based Vitamin D3 manufacturing process. It is addressed to the stock exchange and includes a statement from the Managing Director, background information about the company, and a safe harbor statement. There are no financial statements, regulatory certifications, voting results, or management changes discussed. The document is a corporate announcement about intellectual property and innovation, not a financial report, regulatory filing, or meeting material. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate announcement, which corresponds to Regulatory Filings (RNS). The document length is 7376 characters, which is sufficient for a press release but does not contain detailed financial or governance data. Hence, the classification is RNS with high confidence.
2025-09-12 English
Publication of Notice to equity shareholders
Regulatory Filings
2025-08-22 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.